GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Viridian Therapeutics
Viridian Therapeutics is a biotech company specializing in the treatment of thyroid diseases related to the eye. Its stock price is driven by news of clinical trials. The chart reflects investor confidence in the potential of its targeted therapy.
Share prices of companies in the market segment - Pharma eyes
Viridian Therapeutics is a biotech company specializing in the treatment of thyroid diseases related to the eye. We classify it in the Pharmaceutical Eyes sector, and the chart below shows the dynamics of the entire segment, where the company's value is driven by news of clinical trials.
Broad Market Index - GURU.Markets
Viridian Therapeutics is a biopharmaceutical company developing drugs to treat thyroid diseases associated with the eye. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the overall biotech sector.
Change in the price of a company, segment, and market as a whole per day
VRDN - Daily change in the company's share price Viridian Therapeutics
The change_co indicator for Viridian, a biopharmaceutical company, measures its high volatility. It reflects its sensitivity to the results of clinical trials of its eye disease drugs. This metric is important for biotech risk analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma eyes
Viridian Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with VRDN, a company focused on eye disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Viridian is a biopharmaceutical company specializing in eye care. Ophthalmology is a highly specialized and competitive field. The chart below shows volatility in this sector, allowing you to gauge how Viridian shares react to industry news.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Viridian Therapeutics
Viridian is a biotech company specializing in the treatment of eye diseases. Its stock price depends on clinical trial success and regulatory approvals. These events create unique price movements.
Annual dynamics of market capitalization of the market segment - Pharma eyes
Viridian Therapeutics, Inc. is a biotech company developing drugs to treat thyroid diseases associated with the eye. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Viridian Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Viridian Therapeutics
Viridian, a biotech company specializing in thyroid disease treatments, has sharp monthly fluctuations reflecting the release of clinical trial data, a key factor for companies at this stage of development.
Monthly dynamics of market capitalization of the market segment - Pharma eyes
Viridian Therapeutics is a biotech company specializing in developing treatments for ocular thyroid disease (TED), a serious autoimmune disorder. The chart below illustrates the overall dynamics of the biotech sector, where a focus on unmet medical needs is driving growth.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Viridian Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of thyroid-related eye disease (TED). The company's future depends on the success of its clinical trials. The broader market chart serves only as a backdrop to understand how its potential to develop a better therapy for this disease impacts its stock price.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Viridian Therapeutics
Viridian Therapeutics, a biotech company focused on treating thyroid diseases, shares reflect patient expectations each week. Their price movements reflect progress in clinical trials of their drugs, which could offer new treatment options for underserved populations.
Weekly dynamics of market capitalization of the market segment - Pharma eyes
Ophthalmology-focused biotech is a sector where weekly performance is driven by clinical data. The search for new treatments for eye diseases is a common trend across the board. The chart illustrates this backdrop, which allows one to assess the potential of Viridian Therapeutics.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Viridian Therapeutics develops drugs to treat thyroid diseases. Shares of such innovative biotech companies often move independently of the market. This chart will help you understand: is Viridian living in its own world of clinical trials, or are overall market conditions and risk appetite influencing its stock price?
Market capitalization of the company, segment and market as a whole
VRDN - Market capitalization of the company Viridian Therapeutics
Viridian's market capitalization tells the story of a biotech company focused on treating thyroid diseases associated with the eye. Its volatile price chart reflects progress in clinical trials and investor hopes for a best-in-class drug. Its dynamics tell a story about science, competition, and potential acquisitions.
VRDN - Share of the company's market capitalization Viridian Therapeutics within the market segment - Pharma eyes
Viridian Therapeutics is a biotech company developing drugs to treat thyroid diseases associated with the eye. Its market share reflects the potential of its leading pipeline. Its market capitalization is a bet on success in treating this complex autoimmune disease.
Market capitalization of the market segment - Pharma eyes
Viridian Therapeutics is a biotech company developing drugs to treat thyroid diseases associated with the eye. The chart below shows the overall market capitalization of this sector. Its dynamics reflect the high interest in developing effective treatments for rare autoimmune diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Viridian Therapeutics develops drugs to treat thyroid diseases associated with the eye. Its market capitalization reflects innovation in this niche area of endocrinology. The chart below shows the economic weight of biotech companies solving niche problems.
Book value capitalization of the company, segment and market as a whole
VRDN - Book value capitalization of the company Viridian Therapeutics
Viridian Therapeutics' book value is the capital invested in the development and clinical trials of drugs for the treatment of thyroid diseases associated with the eye. This is a real, scientific foundation, targeting a niche but important medical problem. How has this biotech asset changed? The chart below shows its dynamics.
VRDN - Share of the company's book capitalization Viridian Therapeutics within the market segment - Pharma eyes
Viridian Therapeutics develops drugs for the treatment of thyroid diseases, which requires modern research laboratories. The chart shows the share of these knowledge-intensive tangible assets in the pharmaceutical sector, reflecting the physical foundation of its scientific work.
Market segment balance sheet capitalization - Pharma eyes
Developing drugs to treat rare diseases, as the BCap_Seg chart for biotech shows, is a science-intensive endeavor. Viridian Therapeutics operates in this environment, where its assets are intellectual property and research data, not manufacturing capacity.
Book value of all companies included in the broad market index - GURU.Markets
Viridian Therapeutics' assets are not factories, but a valuable portfolio of developments and patents in the treatment of thyroid diseases associated with the eye. The book value reflects the capital invested in science, which is the foundation for the creation of future, tangible drugs.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Viridian Therapeutics
Viridian Therapeutics is a biotech company focused on treating thyroid diseases. Its MvsBCap story is typical for the sector: its market valuation is a bet on the success of clinical trials. The chart will reflect not the asset value, but the changing probability of its drug candidate reaching the market and being successful.
Market to book capitalization ratio in a market segment - Pharma eyes
Viridian Therapeutics is a biotech company developing drugs to treat thyroid diseases. Its value is based on the potential of its clinical programs. The chart reflects investor expectations regarding the future success of its innovative therapies.
Market to book capitalization ratio for the market as a whole
Viridian Therapeutics is a biotech company developing drugs to treat thyroid diseases. Like other companies in the development stage, its market valuation is a bet on future success. Investors are buying a potential blockbuster, not assets, which explains the large gap between its book value and its assets.
Debts of the company, segment and market as a whole
VRDN - Company debts Viridian Therapeutics
Viridian Therapeutics, a biotech company focused on treating thyroid diseases, allocates all of its raised capital to clinical trials of its drug candidates. This chart illustrates the company's financial position during the R&D phase, when success depends entirely on research results and cash management.
Market segment debts - Pharma eyes
Viridian Therapeutics is a biotech company developing treatments for thyroid diseases related to the eye. Funding R&D for clinical-stage companies is a matter of survival. This chart shows the financial strategy Viridian uses to advance its developments through the expensive stages of clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Viridian Therapeutics
Viridian Therapeutics is a biotech company developing therapies for thyroid diseases. The chart shows how it finances its clinical trials. For a company in the R&D stage with no revenue, raising debt is a bet on future success. Its size reflects investors' confidence in the potential of its developments.
Market segment debt to market segment book capitalization - Pharma eyes
Viridian Therapeutics is a biotech company focused on treating eye diseases. This chart for the biotech sector shows how much capital the industry attracts to fund breakthrough but risky research. It helps understand how the company's financial position is typical for this science-intensive field.
Debt to book value of all companies in the market
Viridian Therapeutics is a biotech company. Its funding depends on investor confidence in its future drugs. This chart reflects the overall risk appetite in the economy. For a company without revenue, it helps understand how its debt or equity financing model compares to the overall market.
P/E of the company, segment and market as a whole
P/E - Viridian Therapeutics
The chart for Viridian Therapeutics, a biopharmaceutical company focused on treating thyroid diseases, shows how investors value its clinical development pipeline. High values reflect expectations for the success of its drugs and significant commercial potential in a market with an unmet need for new treatments.
P/E of the market segment - Pharma eyes
This chart shows the average P/E for the biotech sector where Viridian Therapeutics is developing. The industry's high average valuation reflects hopes for scientific breakthroughs. The chart illustrates this general backdrop against which investors evaluate the potential of Viridian's thyroid treatments.
P/E of the market as a whole
Viridian Therapeutics develops therapeutic drugs for patients with thyroid diseases related to the eye. This is a niche but important area of medicine. This chart of the overall investment climate provides insight into how investors view early-stage biotech companies: as long-term investments in science or as high-risk assets.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Viridian Therapeutics
Viridian Therapeutics is a biotech company developing drugs to treat thyroid diseases associated with the eye. The chart reflects future revenue expectations, which are entirely dependent on the success of clinical trials. Investors are assessing the potential of its therapy to become best-in-class for this patient group.
%20P%2FE%20Viridian%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Viridian-Therapeutics&v=1772632227210 "Chart of the company's future (projected) P/E Viridian Therapeutics")
Future (projected) P/E of the market segment - Pharma eyes
Viridian Therapeutics is a biotech company developing drugs to treat thyroid diseases associated with the eye. This is a highly specialized area with an unmet medical need. The chart shows future profit forecasts for the sector, helping to understand the level of investor confidence in its developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-eyes&v=1772632227213 "Future (projected) P/E graph of the market segment - Pharma eyes")
Future (projected) P/E of the market as a whole
Viridian Therapeutics is a biotech company developing drugs to treat thyroid diseases related to the eye. Its valuation depends on the success of clinical trials. This overall risk appetite chart shows how willing investors are to finance long-term and risky projects in ophthalmology.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772632227236 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Viridian Therapeutics
Viridian Therapeutics is a biotech company focused on developing treatments for thyroid diseases related to the eye. Being in the clinical stage, its financials reflect research expenses. This chart illustrates investments in developing therapies for unmet medical needs in ophthalmology.
Profit of companies in the market segment - Pharma eyes
Viridian Therapeutics is a biotech company developing drugs to treat thyroid diseases associated with the eye. This is a highly specialized area with an unmet medical need. This chart shows the overall profitability of the ophthalmic pharmaceutical sector, where targeted therapies for specific diseases have the potential to establish strong market positions.
Overall market profit
Viridian Therapeutics is a biotech company focused on treating thyroid-related eye diseases. The company's prospects depend on the results of clinical trials and the approval of its drugs. This process is not tied to the economic cycles visible in the chart. Demand for effective treatments is driven by medical needs.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Viridian Therapeutics
Viridian Therapeutics is a biotech company focused on treating thyroid diseases associated with the eye. Future profits are entirely dependent on the success of its lead candidate's clinical trials. This chart reflects analysts' speculative estimates of this drug's market potential.
%20profit%20of%20the%20company%20Viridian%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Viridian-Therapeutics&v=1772632227298 "Graph of future (projected) profit of the company Viridian Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma eyes
Viridian Therapeutics is a biotech company developing drugs to treat thyroid diseases associated with the eye (TED). Its goal is to offer more effective and safer treatments for patients. The company's future depends on clinical trials. This chart shows revenue projections for the ophthalmology pharmaceutical segment, which helps assess Viridian's potential.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-eyes&v=1772632227303 "Graph of future (predicted) profits of companies in a market segment - Pharma eyes")
Future (predicted) profit of the market as a whole
Viridian Therapeutics is a biotech company developing treatments for thyroid diseases related to the eye. Its valuation depends on the success of clinical trials. The overall economic environment, reflected in this chart, influences the availability of capital and investor willingness to fund biotech companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772632227316 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Viridian Therapeutics
Viridian Therapeutics is a biotech company developing drugs to treat thyroid diseases associated with the eye. There is no revenue at the clinical stage. This chart reflects investors' assessment of the potential market for its lead candidate and their belief in the successful completion of clinical trials.
P/S market segment - Pharma eyes
Viridian Therapeutics is a clinical-stage biotech company developing treatments for eye diseases, specifically thyroid eye disease. Their goal is to create best-in-class therapies for patients with serious conditions. This chart reflects the average revenue estimate for the sector, providing insight into market expectations for Viridian's portfolio.
P/S of the market as a whole
Viridian Therapeutics is a biotech company developing treatments for thyroid diseases associated with the eye. The company is targeting a market with an unmet need. This chart illustrates that the valuation of such clinical-stage companies reflects the potential of their therapies, not their current financial performance.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Viridian Therapeutics
Viridian Therapeutics is a biotech company developing drugs to treat thyroid diseases associated with the eye. For a company whose success depends on clinical trial results, valuation based on future revenue is key. It reflects investors' confidence in the potential of its drugs and the likelihood of their future commercial success after approval.
%20P%2FS%20Viridian%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Viridian-Therapeutics&v=1772632227366 "The graph of the company's future (projected) P/S Viridian Therapeutics")
Future (projected) P/S of the market segment - Pharma eyes
Viridian Therapeutics is a biotech company developing treatments for ocular thyroid disease (TED). This chart compares the company's estimated future sales with industry expectations. It shows how investors view the potential of its antibody candidates and their ability to offer TED patients more effective and convenient treatment options.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-eyes&v=1772632227449 "Future (projected) P/S market segment graph - Pharma eyes")
Future (projected) P/S of the market as a whole
Viridian Therapeutics is a biotech company developing drugs to treat thyroid diseases. Its valuation is based on clinical development potential. This chart reflects current projections, while Viridian is betting on future breakthroughs in endocrinology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772632227471 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Viridian Therapeutics
This chart shows the revenue of Viridian Therapeutics, a biotech company developing drugs to treat thyroid diseases associated with the eye. Being in clinical trials, the company may not have commercial sales revenue. Any revenue is likely from partnerships or funding.
Sales of companies in the market segment - Pharma eyes
Viridian Therapeutics is a biotech company developing drugs for the treatment of ocular thyroid disease (TED). Being in the clinical stage, it currently has no revenue. Its future revenue is entirely dependent on the successful development and commercialization of its candidates targeting this specific market.
Overall market sales
Viridian Therapeutics is a biotech company developing treatments for thyroid diseases related to the eye. Its growth and value are driven by progress in clinical trials. This overall market performance chart is just the backdrop for a company operating in a highly specialized, science-driven field of medicine.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Viridian Therapeutics
Viridian Therapeutics is a biotech company developing drugs to treat thyroid diseases associated with the eye. The company is in the clinical stage, and its future revenue depends on the success of its research. This chart shows analysts' forecasts for the potential sales of its lead drug candidate if approved and launched.
%20sales%20of%20the%20company%20Viridian%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Viridian-Therapeutics&v=1772632227710 "Schedule of future (projected) sales of the company Viridian Therapeutics")
Future (projected) sales of companies in the market segment - Pharma eyes
Viridian Therapeutics is a biotech company developing drugs to treat thyroid diseases associated with the eye. This chart shows the forecast for the ophthalmology segment of the pharmaceutical industry. Is the market growing due to the emergence of new treatments? This reflects the overall scientific and commercial potential of the field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-eyes&v=1772632227758 "Schedule of future (projected) sales of companies in the market segment - Pharma eyes")
Future (projected) sales of the market as a whole
Viridian Therapeutics is a biotechnology company developing drugs for the treatment of thyroid diseases. Its prospects are determined solely by the results of clinical trials and the potential of its scientific developments. The general economic trends reflected in this chart have no impact on its operating performance.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772632227772 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Viridian Therapeutics
Viridian Therapeutics is a biotech company developing drugs to treat thyroid diseases associated with the eye. This chart reflects its financial position at the clinical trial stage. Profitability is a future goal, and current metrics demonstrate the level of investment in developing innovative treatments for this underserved market.
Market segment marginality - Pharma eyes
Viridian Therapeutics, Inc. is a clinical-stage biotechnology company developing drugs for the treatment of ocular thyroid diseases. Its financial performance is determined entirely by research and clinical trial expenses. This chart reflects the company's current position, with profitability being a future goal dependent on the success of R&D.
Market marginality as a whole
Viridian Therapeutics is a biotech company developing therapies for thyroid-related eye diseases. Its future depends on the results of clinical trials. This total return chart reflects the investment environment, which is critical for funding expensive research and development in the biotech sector.
Employees in the company, segment and market as a whole
Number of employees in the company Viridian Therapeutics
Viridian Therapeutics is a biotech company developing drugs to treat thyroid diseases associated with the eye. Its staff consists of scientists and clinicians. This graph shows how the team grows as the lead candidate advances through clinical trials, necessitating the hiring of new specialists and increased R&D spending.
Share of the company's employees Viridian Therapeutics within the market segment - Pharma eyes
Viridian Therapeutics is a biotech company developing drugs to treat thyroid diseases associated with the eye. Its activities are focused on clinical research and development. This graph shows the company's share of the biotech labor market, reflecting its progress in developing new drugs and attracting highly qualified specialists.
Number of employees in the market segment - Pharma eyes
Viridian Therapeutics is a biotech company developing treatments for thyroid diseases associated with the eye. The chart illustrates its presence in the ophthalmic pharmaceutical sector. Focusing on a rare but severe disease allows Viridian to pursue best-in-class treatments with high market potential.
Number of employees in the market as a whole
Viridian Therapeutics is a biotech company developing drugs to treat thyroid diseases associated with the eye. The growth of its team of scientists and clinicians reflects advances in the treatment of rare autoimmune disorders. Given the company's overall busy schedule, hiring at Viridian represents an investment in science and improving the quality of life for patients.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Viridian Therapeutics (VRDN)
Viridian Therapeutics is a biotech company. This chart shows how the market values its scientific potential. The company's entire value could be captured in a single promising development. The market capitalization per employee could be extremely high, reflecting not current sales but investor expectations for a future breakthrough in eye disease treatment.
%20of%20the%20company%20Viridian%20Therapeutics%20(VRDN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Viridian-Therapeutics-VRDN&v=1772632228422 "Chart of market capitalization per employee (in thousands of dollars) of the company Viridian Therapeutics (VRDN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma eyes
Viridian Therapeutics (VRDN) is a clinical-stage biotech developing drugs (antibodies) for the treatment of ocular thyroid disease (TED). This chart shows the average market cap per employee in the sector. It helps assess how the market values their R&D portfolio focused on this disease.
%20by%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-eyes&v=1772632228451 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma eyes")
Market capitalization per employee (in thousands of dollars) for the overall market
Viridian Therapeutics is a biotech company developing drugs to treat thyroid diseases. Being in the clinical stage, its value is determined by its future potential. The chart shows a high valuation per employee, as investors factor in the likelihood of successful clinical trials and future market penetration.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772632228462 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Viridian Therapeutics (VRDN)
Viridian is a clinical-stage biotech company specializing in the treatment of thyroid diseases associated with the eye. This graph likely shows the loss per employee. It reflects the investment phase: each employee is a scientist or physician whose work is funded by investors pending drug approval.
%20Chart%20Viridian%20Therapeutics%20(VRDN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Viridian-Therapeutics-VRDN&v=1772632228472 "Company Profit Per Employee (in thousands of dollars) Chart Viridian Therapeutics (VRDN)")
Profit per employee (in thousands of dollars) in the market segment - Pharma eyes
Viridian (VRDN) is an R&D biotech (eye diseases). This chart shows the benchmark for "Pharma" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of money in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-eyes&v=1772632228506 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma eyes")
Profit per employee (in thousands of dollars) for the market as a whole
Viridian Therapeutics is a clinical-stage biotech company specializing in the treatment of thyroid-related eye diseases (TED). It's an R&D company. Like Dianthus, this chart shows the operating loss per employee—the "cost" of conducting expensive clinical trials per research staff.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772632228527 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Viridian Therapeutics (VRDN)
Viridian Therapeutics is a biotech company focused on thyroid diseases. During clinical development, revenue per employee can be low or nonexistent. This graph shows future potential: an approved drug could lead to explosive growth in this metric, demonstrating the value of their intellectual property.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Viridian-Therapeutics-VRDN&v=1772632228588 "Sales chart per company employee Viridian Therapeutics (VRDN)")
Sales per employee in the market segment - Pharma eyes
Viridian Therapeutics is a clinical-stage biotech developing therapies for thyroid diseases (TED). This is pure R&D. This chart shows the average output in the sector. As with other R&D biotechs without stable revenue, this is a leading indicator of the effectiveness of R&D staff expenditures in achieving clinical results.
Sales per employee for the market as a whole
Viridian Therapeutics is a biotech company developing drugs to treat thyroid diseases associated with the eye. Being in the clinical stage, the company has no sales revenue. This indicator reflects ongoing investment in the scientific team working on the development of future drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Viridian Therapeutics (VRDN)
Viridian (VRDN) is a biotech company focused on treating thyroid diseases (specifically, Graves' disease). This chart shows the volume of short positions. These short positions are betting that the company's clinical trials will not show superiority over existing treatments or that the market for the drug will be smaller than expected.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Viridian-Therapeutics-VRDN&v=1772632228662 "Short Shares Chart for the Company Viridian Therapeutics (VRDN)")
Shares shorted by market segment - Pharma eyes
Viridian Therapeutics (VRDN) is a biotech company developing treatments for thyroid diseases, specifically Graves' disease (TED). This chart shows the total short position in the biotech sector. It reflects the high level of risk and investor skepticism regarding clinical trials in this segment.
Shares shorted by the overall market
Viridian (VRDN) is a clinical-stage biotech (eye disease). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives VRDN of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Viridian Therapeutics (VRDN)
Viridian Therapeutics (VRDN) is a biotech company focused on treating eye diseases, specifically thyroid-induced ophthalmopathy (TED). They are striving to develop a best-in-class drug. This chart measures speculative interest. It shows "overheated" (above 70) due to promising clinical data or "oversold" (below 30) due to competitive successes or delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Viridian-Therapeutics-VRDN&v=1772632228728 "RSI 14 indicator chart for the company's stock Viridian Therapeutics (VRDN)")
RSI 14 Market Segment - Pharma eyes
Viridian (VRDN) is a biotech company focused on treating thyroid eye disease (TED), a serious eye condition. The RSI_14_Seg for "Pharma Eyes" (biotech) shows the overall sentiment. The chart helps us understand: is VRDN's volatility a reaction to its trials or is the entire sector overheated?
RSI 14 for the overall market
Viridian (VRDN) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VRDN (Viridian Therapeutics)
Viridian Therapeutics is a biotech company developing drugs to treat thyroid-induced ophthalmopathy (TED), an autoimmune eye disease. This chart shows the average analyst price target, based entirely on their speculative assessment of the likelihood of success in the company's clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VRDN-Viridian-Therapeutics&v=1772632228807 "A chart showing analyst consensus forecasts for the expected stock price. VRDN (Viridian Therapeutics)")
The difference between the consensus estimate and the actual stock price VRDN (Viridian Therapeutics)
Viridian Therapeutics is a biotech company developing innovative drugs for the treatment of ocular thyroid diseases (TED). This chart measures the gap between the current share price and the consensus target price. It shows how confident experts are in the success of their clinical trials and the potential of this niche market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VRDN-Viridian-Therapeutics&v=1772632228813 "A chart showing the difference between the consensus forecast and the actual stock price. VRDN (Viridian Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma eyes
Viridian Therapeutics is a biotech company developing improved (more convenient or effective) versions of existing drugs, primarily for the treatment of thyroid eye disease (TED). This chart shows general expectations for the ophthalmology sector. It reflects whether experts believe in a "fast follower" strategy.
Analysts' consensus forecast for the overall market share price
Viridian Therapeutics (VRDN) is a biopharmaceutical company developing drugs to treat thyroid diseases that affect vision. This is a narrow and complex field. This chart shows the overall risk appetite in the market, reflecting the willingness of investors to fund lengthy and expensive clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Viridian Therapeutics
Viridian Therapeutics is a clinical-stage biotech focused on treating thyroid diseases associated with the eye (TED). This chart represents pure R&D activity. It likely reflects investor confidence in their clinical data and their ability to compete in the potentially large but complex TED treatment market, rather than revenue.
AKIMA Market Segment Index - Pharma eyes
Viridian (VRDN) is a clinical-stage biotech focused on autoimmune diseases; the company is developing innovative antibodies (a competitor to Amgen) for the treatment of thyroid eye disease (TED). This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this niche (TED) R&D focus of VRDN differentiate it from the average pharma company?
The AKIM Index for the overall market
Viridian Therapeutics is a biotech company developing best-in-class drugs for thyroid and eye diseases (TED). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this competitive history with existing blockbusters compares to overall economic trends.
